Corneal Oedema After Cataract Surgery: Causes, Risk Factors, Treatment and Recovery
By Dr Ross MacIntyre MD FRANZCO
Last reviewed: 16 November 2026
Corneal oedema is swelling of the clear front window of the eye. After cataract surgery it is usually mild and temporary, but in some eyes it persists and blurs vision. This page explains why it happens, who is at higher risk, how it is treated, and what happens if it does not clear. It is written for patients and for the optometrists who share their care.
In brief
- Early swelling after cataract surgery usually clears within a few weeks in my practice.
- I call swelling persistent if it remains beyond 3 months.
- Higher-risk eyes include those with Fuchs dystrophy, past or active uveitis, high eye pressure, or previous glaucoma surgery.
- Treatment is mostly steroid drops, hypertonic saline and pressure control. Some glaucoma drops are best avoided in a fragile cornea.
- If swelling does not recover, a corneal transplant of the inner layer (endothelial keratoplasty) can be considered.
What is corneal oedema after cataract surgery?
Corneal oedema is swelling of the cornea, the clear window at the front of the eye. A single layer of cells on its inner surface, the endothelium, pumps fluid out to keep it clear. Surgery can stress or damage these cells, so the cornea may take on fluid and look hazy.
Patients usually notice blurred, misty or glary vision, often worst in the morning. Surgery always removes some endothelial cells. In a randomised trial of 500 patients (433 completed), the average loss was about 10% at one year (Bourne 2004). Most eyes have enough reserve that this does not matter. Swelling appears when too few cells remain, or the remaining cells cannot cope.
How common is it, and how long does it take to clear?
In my practice, early swelling usually clears within a few weeks. I call swelling persistent if it remains beyond 3 months. I could find no study that measures what proportion of early swelling clears, or how quickly, so these timings are clinical experience, not a published figure.
The nearest published data are limited. In a series of striate keratopathy after manual small-incision surgery, it resolved in 97.3% of patients irrespective of hypertonic saline treatment, and 92% had 6/9 vision or better at 6 to 10 weeks (Rajappa 2022). Cataract surgery was the most common cause of bullous keratopathy, the late stage of persistent swelling, in a Japanese national survey of 963 eyes (Shimazaki 2007).
What causes the cornea to swell after cataract surgery?
Swelling follows damage to the endothelial cells, or to their pumping ability. The damage can come from ultrasound energy, mechanical contact, inflammation, or a pressure rise. A harder lens nucleus means more energy and more cell loss. Eyes that were already fragile are the most likely to swell.
- Hard cataract and older age were associated with excess cell loss (15% or more at one year) in the randomised trial above (Bourne 2004). Nucleus firmness was the most significant factor in a study of 859 eyes (Hayashi 1996), and shorter axial length and longer phacoemulsification time were the significant factors in a 50-patient series (Walkow 2000).
- Pseudoexfoliation: cell loss was 9.0% versus 3.4% in non-pseudoexfoliation eyes (Hayashi 2013, 36 eyes per group).
- Complications. Descemet membrane detachment is uncommon (0.044% per year at one centre). Pre-existing endothelial disease and corneal oedema on the first post-operative day were risk factors, and an air bubble restored corneal clarity in 14 of 16 treated eyes (87.5%), by 30 days (range 4 to 82) (Ti 2013). Retained lens fragments occurred in 0.124% of 98,467 uneventful phacoemulsification operations, and 6 of 122 affected eyes (4.9%) had persistent oedema needing endothelial keratoplasty (Matarazzo 2021).
- Toxic anterior segment syndrome (TASS) typically begins 12 to 48 hours after surgery and usually improves with steroid treatment (Mamalis 2006).
Does Fuchs dystrophy or a low cell count increase the risk?
Yes. Fuchs endothelial dystrophy means the endothelium is already failing, so it has little reserve for surgery. Cataract surgery can tip an eye with Fuchs from coping into swelling. Eyes with guttae (small drops on the inner surface) or a thick cornea before surgery are at higher risk.
In a prospective multicentre study of 178 eyes with Fuchs and cataract, 21% (38 eyes) met the criteria for endothelial keratoplasty, and 82% of those events occurred within 6 months of phacoemulsification (Arnalich-Montiel 2026). In a 52-eye randomised trial in Fuchs, corneal thickness before surgery was the only significant predictor of decompensation, with risk rising above about 620 microns (Doors 2013). Fuchs is usually detected before surgery with a slit lamp examination, pachymetry and specular microscopy. See our guide to Fuchs endothelial dystrophy.
I could not find an agreed cell-count threshold below which cataract surgery is unsafe. Decisions are individual.
Does uveitis increase the risk of corneal oedema after cataract surgery?
Uveitis is a recognised risk factor in clinical practice, and in my practice it is a reason to plan surgery carefully. Eyes with uveitis may have more inflammation, need stronger steroid treatment, and have more pressure problems. Some forms of uveitis also directly affect the endothelium.
The published evidence is patchy and mostly about specific conditions, so I cannot give a general risk figure. I found no study measuring corneal oedema after cataract surgery in uveitic eyes as a group. In 31 patients with Fuchs heterochromic iridocyclitis, the affected eye had significantly lower endothelial density than the fellow eye (Sravani 2020). In 52 eyes with cytomegalovirus-positive Posner-Schlossman syndrome, endothelial counts were lower than in the fellow eye (2,242 versus 2,529 cells/mm²) (Lenglinger 2022), and about two-thirds of cytomegalovirus endotheliitis cases present with high eye pressure and coin-shaped corneal lesions (La Distia Nora 2022). After trabeculectomy, uveitic glaucoma was a significant predictor of endothelial cell loss (Hirooka 2020). A review of herpetic eye disease estimated recurrence after cataract surgery at about 40%, mostly keratitis within two years, although the studies were too varied to analyse systematically (Drew-Bear 2025).
How do high eye pressure and glaucoma affect the cornea after cataract surgery?
High eye pressure stresses the endothelium, and a long or severe pressure rise can leave it permanently weakened. Eyes with angle-closure attacks, uncontrolled glaucoma, or a pressure spike after surgery are at higher risk. Pressure should be controlled before and after surgery, and pressure readings in a swollen cornea can be misleading.
After a single episode of acute angle closure in 171 eyes, 12.28% had an endothelial cell density below 1,000 per mm², and attack duration was the only factor associated with severe damage (Li 2023). Pressure checks themselves can mislead. In 136 patients on day 1 after phacoemulsification, greater corneal oedema was associated with lower applanation readings, and a 7% increase in thickness corresponded to an 8 mmHg underestimate in the authors' models (Huang 2011). Pressure-lowering prophylaxis around surgery lowered pressure at 2 to 8 hours (3.87 mmHg lower on average across 30 randomised trials of 2,986 eyes), but those trials measured pressure, not corneal outcomes (Kanjee 2024). Laser iridotomy was the second most common cause of bullous keratopathy in the Japanese survey, developing a mean of 6.8 years after the laser (Shimazaki 2007).
Does previous glaucoma surgery increase the risk of corneal swelling?
It can. Glaucoma operations that place hardware in the eye, particularly drainage tubes, are linked to ongoing endothelial cell loss. The effect depends on the procedure and the tube position. If you have had glaucoma surgery, ask whether your cornea has been checked, because cell loss can continue for years.
A meta-analysis of 39 studies found average endothelial loss of 282 cells/mm² at 12 months after suprachoroidal minimally invasive glaucoma surgery (very low certainty), compared with 33 cells/mm², not significant, after trabeculectomy (moderate certainty). It found low-certainty evidence that long-term implants cause more loss, and advised follow-up beyond 36 months for drainage implants (Fang 2022). A prospective series of 117 eyes still found cell density fell continuously after trabeculectomy (2,420 to 2,267 cells/mm² at 2 years) (Hirooka 2020), so findings are mixed. For tubes, a prospective study of 53 eyes reported a mean central loss of 4.54% per year, with less loss in the nearby peripheral cornea when the tube passed through the iris than when it lay free in the anterior chamber, and more loss with a shorter tube-to-cornea distance (Tan 2017). In another series, bullous keratopathy was more common with limbal tube insertion than insertion through the pars plana, and low pre-operative cell density was a significant risk factor (Chihara 2023). In eyes with a prior drainage device, pooled 36-month graft survival after endothelial keratoplasty was 50%, from 22 retrospective studies (Irigoyen-Bañegil 2026). See cataract surgery in glaucoma and iStent and SLT.
How is early corneal swelling treated?
Treatment aims to protect the endothelium while it recovers. In my practice that means a little extra steroid for inflammation, hypertonic saline drops for comfort and clearing, and lowering pressure if it is raised. I avoid carbonic anhydrase inhibitors, because they can affect the endothelial pump.
Evidence is limited for each step. In a randomised trial of 183 eyes after uneventful phacoemulsification, 5% saline drops reduced corneal thickness more than placebo by day 4 (10.73% versus 7.39%), and 92.4% versus 57.1% reported clear vision at one week (Tzamalis 2020). In another randomised study of 86 patients with postoperative oedema, vision was better at 7 days with hypertonic saline-hyaluronate drops (0.84 versus 1.55 logMAR) and no longer different from one month; the thickness difference was not significant (Ho Wang Yin 2015). I found no trial of steroids for oedema recovery. For carbonic anhydrase inhibitors: in eyes with guttae the cornea thickened more on dorzolamide than on saline (12.0 versus 0.6 microns in 24 hours, Wirtitsch 2003; 26.3 versus 3.3 microns at 4 weeks, Wirtitsch 2007), and irreversible oedema was reported in nine eyes, all after intraocular surgery (Konowal 1999). In a 298-patient randomised trial, dorzolamide, timolol and betaxolol gave equivalent cell loss, but it enrolled only eyes with counts above 1,500 cells/mm² (Lass 1998). Topical carbonic anhydrase inhibitors were also among the least effective drops for preventing early pressure spikes after surgery (Kanjee 2024). Descemet membrane detachments may resolve on their own or need an air or gas bubble (Singhal 2020 review).
What if the cornea does not recover?
If swelling persists beyond 3 months, endothelial keratoplasty is considered. This replaces only the diseased inner layer of the cornea with donor tissue, either Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK), depending on the eye. I wait at least 3 months before considering it.
No randomised trial has defined the best time to operate. In a 50-eye randomised trial, DMEK gave 1.5 lines better acuity at 3 months than ultrathin DSAEK (Chamberlain 2019). In another, acuity did not differ significantly at 3, 6 or 12 months, although more DMEK eyes reached 20/25 at 12 months (66% versus 33%) (Dunker 2020). These trials were mostly in Fuchs, not oedema after cataract surgery. In one comparative series, cumulative rejection at 2 years was 1% for DMEK, 12% for DSEK and 18% for penetrating keratoplasty, in a cohort that was mostly Fuchs (Anshu 2012). In 2,956 Fuchs eyes at one German centre, DMEK and DSAEK gave faster visual recovery (median 7.8 and 12.4 months to 6/12, versus 37.9 for penetrating keratoplasty), but penetrating keratoplasty had better 10-year graft survival (92% versus 75% for DMEK and 73% for DSAEK), while DMEK had the lowest rejection (10%) (Wilhelm 2025). These results come from Fuchs eyes, and the abstracts do not define graft survival, so the figures should not be applied directly to oedema after cataract surgery. See corneal transplant options and corneal surgery.
Are ROCK inhibitor drops or cell therapy options?
They are experimental. Rho kinase (ROCK) inhibitors such as ripasudil and netarsudil have been studied for corneal oedema, mainly in Fuchs dystrophy. They are not proven for oedema after cataract surgery, and no Australian Register of Therapeutic Goods (ARTG) entry was found for ripasudil or netarsudil on 16 November 2026.
In a randomised placebo-controlled trial of 48 Fuchs eyes, ripasudil drops for one month after phacoemulsification reduced paracentral cell loss at 3 months (0.4% versus 7.3%), without a significant difference in corneal thickness (Keeratidamkerngsakul 2025). An open-label randomised trial of 41 eyes found thickness stayed stable with ripasudil before femtosecond laser cataract surgery but rose in controls (Gaudenzi 2025). In a retrospective ripasudil series, thickness fell by 30.44 microns and acuity improved by 0.27 logMAR in the post-cataract-surgery group (Erdinest 2025). In 13 eyes with persistent oedema after intraocular surgery, once-daily netarsudil-latanoprost for 3 months reduced thickness by an average of 120 microns, and oedema cleared completely in 38% (Kobal Mikša 2026). The last two are small uncontrolled series. A phase 3 trial of ripasudil in Fuchs eyes undergoing femtosecond laser cataract surgery (NCT06048380) has posted no results. In Australia, ripasudil is not an approved medicine (no ARTG entry was found on 16 November 2026). Any use is a decision for the treating ophthalmologist, case by case, and cost can be a barrier. Cultured endothelial cell injection therapy is investigational (Kinoshita 2018, 11 eyes; Kinoshita 2025, 65 patients).
For optometrists
For optometrists: what should I look for, and when should I refer?
Check vision, corneal clarity and thickness, pressure, and inflammation at each post-operative visit. Swelling that is not improving by week 6, pressure above 30 mmHg or not responding to topical medication, increasing oedema, or pain should be referred back promptly. These are my practice thresholds, not validated criteria.
- Ask about morning blur and glare. Look for stromal haze, epithelial bullae, Descemet folds, and striae.
- Measure pressure, and remember applanation readings can be falsely low in an oedematous cornea (Huang 2011), so a normal reading does not exclude a pressure problem. If pressure is high, discuss the choice of drop with the surgeon before starting a carbonic anhydrase inhibitor.
- Look for Descemet membrane detachment near the corneal incision, particularly if oedema was marked on day 1 or the patient has endothelial disease (Ti 2013).
- Pachymetry or anterior segment OCT is useful for tracking thickness. OCT thickness mapping may help detect preclinical oedema in Fuchs eyes before surgery (Guindolet 2023).
- Flag higher-risk patients before surgery: Fuchs, low cell count, thick cornea, uveitis, high pressure, previous glaucoma surgery or a tube, previous laser iridotomy.
- Urgent same-day referral: severe pain, rapidly worsening vision, marked haze or hypopyon, which may indicate TASS or infection.
- No validated optometrist referral criteria exist in the published literature that I could find.
See our guidance for optometrists.
What does the research not tell us?
Several practical questions have no good published answer. I could not find a study of how many early swellings clear and how fast, a randomised trial of timing for keratoplasty after cataract surgery, or a trial of medical treatment in this setting. Uveitis-specific data are sparse. Treat the timings above as clinical judgement.
Evidence for ROCK inhibitors in this setting comes from small studies. Graft survival comparisons between DMEK and penetrating keratoplasty vary with definitions and follow-up. Data on tubes and corneal outcomes often need full-text review. Where the evidence ends, I have said "in my practice".
Sources
- Bourne RR et al. Effect of cataract surgery on the corneal endothelium: modern phacoemulsification compared with extracapsular cataract surgery. Ophthalmology. 2004.
- Walkow T et al. Endothelial cell loss after phacoemulsification: relation to preoperative and intraoperative parameters. J Cataract Refract Surg. 2000.
- Hayashi K et al. Risk factors for corneal endothelial injury during phacoemulsification. J Cataract Refract Surg. 1996.
- Hayashi K et al. Corneal endothelial damage after cataract surgery in eyes with pseudoexfoliation syndrome. J Cataract Refract Surg. 2013.
- Ti SE et al. Descemet membrane detachment after phacoemulsification surgery: risk factors and success of air bubble tamponade. Cornea. 2013.
- Matarazzo F et al. Incidence and complications of retained lens fragment in the anterior chamber after uneventful cataract surgery in a United Kingdom tertiary center. J Cataract Refract Surg. 2021.
- Mamalis N et al. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006.
- Shimazaki J et al. National survey on bullous keratopathy in Japan. Cornea. 2007.
- Arnalich-Montiel F et al. Validation and extension of the SUCCESS score for Fuchs dystrophy after cataract surgery. Eye Vis (Lond). 2026.
- Doors M et al. Phacopower modulation and the risk for postoperative corneal decompensation: a randomized clinical trial. JAMA Ophthalmol. 2013.
- Sravani NG et al. Corneal endothelium in unilateral Fuchs heterochromic iridocyclitis. Indian J Ophthalmol. 2020.
- Lenglinger M et al. Cytomegalovirus-Positive Posner-Schlossman Syndrome: Impact on Corneal Endothelial Cell Loss and Retinal Nerve Fiber Layer Thinning. Am J Ophthalmol. 2022.
- La Distia Nora R et al. Clinical characteristics and treatment outcomes of cytomegalovirus anterior uveitis and endotheliitis: A systematic review and meta-analysis. Surv Ophthalmol. 2022.
- Drew-Bear LE et al. Recurrence of herpetic keratouveitis following cataract surgery. Int Ophthalmol. 2025.
- Li Z et al. Factors associated with severe corneal endothelial damage following acute primary angle closure in Chinese subjects. Graefes Arch Clin Exp Ophthalmol. 2023.
- Huang Y et al. Determinants of postoperative corneal edema and impact on goldmann intraocular pressure. Cornea. 2011.
- Kanjee R et al. Prophylaxis against intraocular pressure spikes following uncomplicated phacoemulsification: a systematic-review and meta-analysis. Eye (Lond). 2024.
- Fang CEH et al. Corneal Endothelial Cell Density Loss after Glaucoma Surgery Alone or in Combination with Cataract Surgery: A Systematic Review and Meta-analysis. Ophthalmology. 2022.
- Hirooka K et al. Effect of trabeculectomy on corneal endothelial cell loss. Br J Ophthalmol. 2020.
- Tan AN et al. Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber. Acta Ophthalmol. 2017.
- Chihara E et al. Different patterns in the corneal endothelial cell loss after pars plana and pars limbal insertion of the Baerveldt glaucoma implant. Am J Ophthalmol. 2023.
- Irigoyen-Bañegil C et al. Endothelial Keratoplasty in Eyes With Previous Glaucoma Surgery: A Systematic Review and Meta-Analysis Stratified by Graft Technique. Am J Ophthalmol. 2026.
- Tzamalis A et al. Safety and efficacy of hypertonic saline solution (5%) versus placebo in the treatment of postoperative corneal edema after uneventful phacoemulsification: a randomized double-blind study. Int Ophthalmol. 2020.
- Ho Wang Yin G et al. [Visual acuity, pachymetry and corneal density after 5% sodium chloride treatment in corneal edema after surgery]. J Fr Ophtalmol. 2015.
- Rajappa SA et al. Evaluation of striate keratopathy after manual small-incision cataract surgery and its final outcomes in a tertiary hospital. Indian J Ophthalmol. 2022.
- Wirtitsch MG et al. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol. 2003.
- Wirtitsch MG et al. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol. 2007.
- Konowal A et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999.
- Lass JH et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998.
- Singhal D et al. Descemet membrane detachment. Surv Ophthalmol. 2020.
- Chamberlain W et al. Descemet Endothelial Thickness Comparison Trial: A Randomized Trial Comparing Ultrathin Descemet Stripping Automated Endothelial Keratoplasty with Descemet Membrane Endothelial Keratoplasty. Ophthalmology. 2019.
- Dunker SL et al. Descemet Membrane Endothelial Keratoplasty versus Ultrathin Descemet Stripping Automated Endothelial Keratoplasty: A Multicenter Randomized Controlled Clinical Trial. Ophthalmology. 2020.
- Anshu A et al. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. Ophthalmology. 2012.
- Wilhelm TI et al. Ten-year outcomes after DMEK, DSAEK, and PK: insights on graft survival, endothelial cell density loss, rejection and visual acuity. Sci Rep. 2025.
- Keeratidamkerngsakul B et al. Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification. Cornea. 2025.
- Gaudenzi D et al. Rock-Inhibitors eyedrops preventing cataract surgery induced corneal failure in Fuchs corneal dystrophy. Eur J Ophthalmol. 2025.
- Erdinest N et al. Clinical Evaluation of Ripasudil for Corneal Edema: A Large-Scale Retrospective Cohort Study. J Clin Med. 2025.
- Kobal Mikša N et al. Rho-Kinase Inhibitor-A Molecule for Pharmacological Treatment of Decompensated Corneas: Case Series. Biomedicines. 2026.
- Kinoshita S et al. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. N Engl J Med. 2018.
- Kinoshita S et al. Long-term Corneal Rejuvenation after Transplantation of Cultured Human Corneal Endothelial Cells. Ophthalmology. 2025.
- Guindolet D et al. Detecting Subclinical Corneal Edema Using Corneal Thickness Mapping in Patients Presenting Fuchs Endothelial Corneal Dystrophy. Am J Ophthalmol. 2023.